Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
Conditions: Bladder Cancer; Muscle-Invasive Bladder Carcinoma; Stage II Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8

Interventions: Drug: Enfortumab Vedotin; Biological: Pembrolizumab; Radiation: Intensity Modulated Radiation Therapy (IMRT); Procedure: Transurethral Resection of Bladder Tumor; Procedure: Cystoscopy (CS); Procedure: Computed Tomography (CT); Procedure: Magnetic Resonance Imaging (MRI); Procedure: Positron Emission Tomography (PET)

Sponsors: University of California, San Francisco; Astellas Pharma Inc; Merck Sharp & Dohme LLC

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 25, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments